Johnson & Johnson discontinued prizlo-cel in May. The drug worked. That was not enough.
13 min read
Therapeutic
Therapeutic Thursday: The Field Is Sorting Itself. Watch Who Is Leaving and Why.
Cell and gene therapy has its first commercial products, its first profitable company, and its first wave of strategic exits. The exits are as informative as the deals.
